Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 119

Similar articles for PubMed (Select 22460814)


Phosphatidylinositol-3-kinase pathway mutations are common in breast columnar cell lesions.

Troxell ML, Brunner AL, Neff T, Warrick A, Beadling C, Montgomery K, Zhu S, Corless CL, West RB.

Mod Pathol. 2012 Jul;25(7):930-7. doi: 10.1038/modpathol.2012.55. Epub 2012 Mar 30.


Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions.

Ang DC, Warrick AL, Shilling A, Beadling C, Corless CL, Troxell ML.

Mod Pathol. 2014 May;27(5):740-50. doi: 10.1038/modpathol.2013.197. Epub 2013 Nov 1.


Mucinous breast carcinomas lack PIK3CA and AKT1 mutations.

Kehr EL, Jorns JM, Ang D, Warrick A, Neff T, Degnin M, Lewis R, Beadling C, Corless CL, Troxell ML.

Hum Pathol. 2012 Dec;43(12):2207-12. doi: 10.1016/j.humpath.2012.03.012. Epub 2012 Jun 15.


Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma.

Dunlap J, Le C, Shukla A, Patterson J, Presnell A, Heinrich MC, Corless CL, Troxell ML.

Breast Cancer Res Treat. 2010 Apr;120(2):409-18. doi: 10.1007/s10549-009-0406-1. Epub 2009 May 6.


High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.

Troxell ML, Levine J, Beadling C, Warrick A, Dunlap J, Presnell A, Patterson J, Shukla A, Olson NR, Heinrich MC, Corless CL.

Mod Pathol. 2010 Jan;23(1):27-37. doi: 10.1038/modpathol.2009.142. Epub 2009 Nov 6.


PIK3CA-AKT pathway mutations in micropapillary breast carcinoma.

Flatley E, Ang D, Warrick A, Beadling C, Corless CL, Troxell ML.

Hum Pathol. 2013 Jul;44(7):1320-7. doi: 10.1016/j.humpath.2012.10.018. Epub 2013 Jan 24.


PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast.

Li H, Zhu R, Wang L, Zhu T, Li Q, Chen Q, Wang H, Zhu H.

Exp Mol Pathol. 2010 Feb;88(1):150-5. doi: 10.1016/j.yexmp.2009.09.016. Epub 2009 Oct 8.


Molecular alterations in columnar cell lesions of the breast.

Dabbs DJ, Carter G, Fudge M, Peng Y, Swalsky P, Finkelstein S.

Mod Pathol. 2006 Mar;19(3):344-9.


PIK3CA mutations in in situ and invasive breast carcinomas.

Miron A, Varadi M, Carrasco D, Li H, Luongo L, Kim HJ, Park SY, Cho EY, Lewis G, Kehoe S, Iglehart JD, Dillon D, Allred DC, Macconaill L, Gelman R, Polyak K.

Cancer Res. 2010 Jul 15;70(14):5674-8. doi: 10.1158/0008-5472.CAN-08-2660. Epub 2010 Jun 15.


PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression.

Kalinsky K, Heguy A, Bhanot UK, Patil S, Moynahan ME.

Breast Cancer Res Treat. 2011 Sep;129(2):635-43. doi: 10.1007/s10549-011-1601-4. Epub 2011 May 27.


Frequent PIK3CA mutations in radial scars.

Wolters KL, Ang D, Warrick A, Beadling C, Corless CL, Troxell ML.

Diagn Mol Pathol. 2013 Dec;22(4):210-4. doi: 10.1097/PDM.0b013e318288b346.


p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias.

Done SJ, Arneson NC, Ozçelik H, Redston M, Andrulis IL.

Cancer Res. 1998 Feb 15;58(4):785-9.


Novel method for PIK3CA mutation analysis: locked nucleic acid--PCR sequencing.

Ang D, O'Gara R, Schilling A, Beadling C, Warrick A, Troxell ML, Corless CL.

J Mol Diagn. 2013 May;15(3):312-8. doi: 10.1016/j.jmoldx.2012.12.005. Epub 2013 Mar 27.


PIK3CA gene mutations in breast carcinoma in Malaysian patients.

Ching-Shian Leong V, Jabal MF, Leong PP, Abdullah MA, Gul YA, Seow HF.

Cancer Genet Cytogenet. 2008 Dec;187(2):74-9. doi: 10.1016/j.cancergencyto.2008.07.005.


Initiating breast cancer by PIK3CA mutation.

Miller TW.

Breast Cancer Res. 2012 Feb 7;14(1):301.


Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations.

Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O.

Mod Pathol. 2012 Apr;25(4):615-24. doi: 10.1038/modpathol.2011.189. Epub 2011 Dec 9.


Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women.

Maruyama N, Miyoshi Y, Taguchi T, Tamaki Y, Monden M, Noguchi S.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):408-14. Epub 2007 Jan 3.


Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection.

Hernandez L, Wilkerson PM, Lambros MB, Campion-Flora A, Rodrigues DN, Gauthier A, Cabral C, Pawar V, Mackay A, A'hern R, Marchiò C, Palacios J, Natrajan R, Weigelt B, Reis-Filho JS.

J Pathol. 2012 May;227(1):42-52. doi: 10.1002/path.3990. Epub 2012 Mar 21.


The timing and characterization of p53 mutations in progression from atypical ductal hyperplasia to invasive lesions in the breast cancer.

Kang JH, Kim SJ, Noh DY, Choe KJ, Lee ES, Kang HS.

J Mol Med (Berl). 2001 Nov;79(11):648-55.


Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin.

Cufí S, Corominas-Faja B, Lopez-Bonet E, Bonavia R, Pernas S, López IÁ, Dorca J, Martínez S, López NB, Fernández SD, Cuyàs E, Visa J, Rodríguez-Gallego E, Quirantes-Piné R, Segura-Carretero A, Joven J, Martin-Castillo B, Menendez JA.

Oncotarget. 2013 Sep;4(9):1484-95.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk